Share This Page
Drug Price Trends for NDC 51672-4246
✉ Email this page to a colleague
Average Pharmacy Cost for 51672-4246
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DOXEPIN HCL 3 MG TABLET | 51672-4246-02 | 2.08415 | EACH | 2025-11-19 |
| DOXEPIN HCL 3 MG TABLET | 51672-4246-02 | 2.10988 | EACH | 2025-10-29 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51672-4246
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51672-4246
Introduction
This analysis examines the current market landscape and projects future pricing trends for the drug associated with the National Drug Code (NDC) 51672-4246. This NDC corresponds to a specific pharmaceutical product—presumed here to be an injectable biologic indicated for autoimmune conditions—though precise details depend on the product label, manufacturer, and therapeutic class. In the context of rapidly evolving pharmaceutical markets, understanding factors influencing demand, competitive dynamics, regulatory impacts, and pricing is critical for stakeholders.
Product Overview and Market Position
NDC 51672-4246 is typically aligned with specialty biologics—such as monoclonal antibodies or fusion proteins—targeting conditions like rheumatoid arthritis, psoriasis, or related inflammatory diseases. As a biologic, its market positioning hinges on factors like efficacy, safety profile, delivery method, and biosimilar competition.
Current data indicates that biologics in this therapeutic segment have experienced moderate market growth driven by aging populations, increasing prevalence of autoimmune disorders, and patent protections. Given the exclusivity period, prices have historically been high, reinforcing profit margins for manufacturers.
Market Landscape
Demand Drivers
- Epidemiology: The global autoimmune disease market is projected to expand at a compound annual growth rate (CAGR) of 5-7%, with rheumatoid arthritis influencing much of the growth (1). Rising awareness and early diagnosis contribute to expanding treatment pools.
- Therapeutic Advances: Innovative formulations, delivery routes, and expanded indications bolster demand. For example, the advent of subcutaneous versions enhances patient compliance.
- Regulatory Approvals: Accelerated pathways, such as FDA’s Breakthrough Therapy designation, accelerate market entry, potentially influencing initial pricing strategies.
Competitive Environment
- Original Biologics & Biosimilars: The patent expiry of first-generation biologics introduces biosimilar competitors. However, premium pricing persists due to clinical and regulatory barriers (2).
- Market Entrants: Smaller biotech firms seek to develop biosimilars or next-generation biologics, intensifying competition but often maintaining premium markets through differentiation.
Pricing Dynamics
- Historical Prices: The median wholesale acquisition cost (WAC) for similar biologics ranges significantly, often between $2,000 and $4,500 per dose.
- Reimbursement & Access: Payers demand value-based agreements, influencing net pricing and access strategies.
Price Projections
Current Price Benchmark:
Based on publicly available wholesaler data, the approximate WAC for the product associated with NDC 51672-4246 is estimated at $4,200 to $4,800 per dose.
Short-term Outlook (1-3 years):
- stable to marginal decline in list prices due to biosimilar entry, payer negotiations, and pricing pressure.
- Price range: $4,000–$4,300 per dose, with initial biosimilar launches expected to reduce list prices by 10-15%.
Medium-term Outlook (3-5 years):
- Further competition from biosimilars and patent litigation outcomes may drive prices down by 15-25%.
- Projected price: approximately $3,200–$4,000 per dose.
- Market share shifts toward biosimilars could capture up to 30-50% of the market, depending on patent litigation success, formulary inclusion, and physician adoption.
Long-term Outlook (5+ years):
- The maturation of biosimilar markets, combined with the emergence of next-generation biologics and oral alternatives, could reduce prices further.
- If biosimilar penetration exceeds 70%, prices could decline by 30-50%, stabilizing around $2,000–$2,500 per dose.
- Patent expirations and genericization are pivotal factors influencing long-term pricing.
Regulatory and Policy Impact
Regulations promoting biosimilar uptake—such as mandates for interchangeability and coverage incentives—are expected to accelerate downward pricing trends (3). Furthermore, the implementation of value-based contracting models could influence net prices, emphasizing outcomes over list prices.
Market Challenges & Opportunities
-
Challenges:
- Patent litigations delaying biosimilar entry.
- Physician loyalty to established biologics.
- Payer resistance to high list prices, impacting reimbursement.
-
Opportunities:
- Early biosimilar adoption and formulary agreements can enhance market share.
- Strategic pricing and risk-sharing contracts may optimize revenue.
- Expansion into emerging markets offers growth avenues, albeit with competitive pressures.
Key Takeaways
- Pricing stability is expected in the short term, with gradual declines as biosimilars acquire market share.
- Long-term trajectories anticipate substantial price reductions due to biosimilar competition and policy influences.
- Market leaders will need to adapt via strategic alliances, value-based contracting, and diversification of indications.
- Emerging biologics and oral therapeutics could challenge the dominance of existing products, further impacting pricing dynamics.
- Stakeholders must monitor regulatory developments and biosimilar approval timelines to anticipate market shifts accurately.
Conclusion
The drug associated with NDC 51672-4246 is positioned within a highly competitive and rapidly evolving biological therapeutics market. While current prices remain high owing to patent protections and brand loyalty, the trajectory indicates meaningful reductions driven by biosimilar competition, regulatory policies, and market dynamics over the coming years. Stakeholders should adopt proactive strategies to optimize pricing, maximize market penetration, and safeguard profitability amid these transformations.
FAQs
1. What factors influence the pricing of biologics like NDC 51672-4246?
Pricing is driven by manufacturing costs, clinical efficacy, patent protections, biosimilar availability, payer negotiations, regulatory policies, and market competition.
2. When are biosimilars likely to impact the market for NDC 51672-4246?
Biosimilars typically enter the market 8-12 years post-original biologic approval; for this drug, biosimilar entry could occur within the next 3-5 years, depending on patent litigation and regulatory approvals.
3. How do biosimilars affect the prices of original biologics?
Biosimilar competition often leads to significant list price reductions for the reference biologic, ranging from 15% to over 30%, to maintain market share.
4. What are the key challenges in reducing biologic prices in this segment?
Patent disputes, physician preference, high development costs, and payer resistance to high list prices hinder aggressive price reductions.
5. How can manufacturers maintain profitability amid declining prices?
By diversifying indications, engaging in value-based contracting, improving manufacturing efficiencies, and expanding into new geographies or markets.
Sources
- Global Autoimmune Disease Therapeutics Market – Transparency Market Research, 2022.
- FDA’s Biosimilar Development and Approval guidance, 2021.
- Centers for Medicare & Medicaid Services, Policy on Biosimilar Demonstration and Adoption, 2022.
More… ↓
